MDXHealth SA (NASDAQ:MXDHF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Friday. The firm presently has a $6.25 price objective on the stock.

According to Zacks, “MDxHealth SA is a healthcare company which provides actionable molecular diagnostic information for diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation and other molecular technologies and assist physicians with the diagnosis of cancer. MDxHealth SA is headquartered in Herstal, Belgium. “

Shares of MDXHealth SA (MXDHF) remained flat at $5.90 on Friday. MDXHealth SA has a 52 week low of $3.80 and a 52 week high of $6.15. The firm’s market capitalization is $294.70 million. The company has a 50-day moving average of $5.75 and a 200 day moving average of $5.67.

WARNING: This report was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/09/16/zacks-investment-research-upgrades-mdxhealth-sa-mxdhf-to-buy.html.

Get a free copy of the Zacks research report on MDXHealth SA (MXDHF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MDXHealth SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MDXHealth SA and related companies with MarketBeat.com's FREE daily email newsletter.